Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06798480
Starting soon Observational

Prevalence of Problematic Use of Social Media

NCT06798480 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-04-01
Last updated
2025-03-05

Condition(s) studied

Social NetworksAddiction

Investigational drug(s) / intervention(s)

Self-administered survey

Self-administered survey: An anonymous self-administered online questionnaire hosted on LimeSurvey, lasting approximately 20 minutes, will be completed by participants. A panel of participants representative of the general population will be provided by the Selvitys Institute. In parallel, the self-administered questionnaire will also be distributed via posts on social media platforms (Facebook, YouTube, Instagram, TikTok, Snapchat, and X) over a period of three months.

Study summary

In 2023, French individuals spend an average of two hours per day on social media platforms (SM), primarily Facebook, TikTok, X, YouTube, Instagram, and Snapchat. While social media offers undeniable benefits, it also raises concerns about its impact on mental health and well-being. These impacts remain poorly understood, partly due to the diversity of social media uses and motivations, which do not have uniform effects on health. For instance, studies have shown that "active" use of social media (e.g., content creation) is associated with higher well-being, whereas "passive" use (e.g., content scrolling) is linked to lower well-being.

This challenge in understanding the variety of social media uses and their consequences has direct clinical implications. Clinicians working in pediatrics, child psychiatry, and addiction medicine are increasingly confronted with patients struggling to manage their social media use. However, they lack clear diagnostic criteria to differentiate between normal and problematic use, as well as specific tools tailored to address potential disorders.

Moreover, in France, there is no existing estimate of the proportion of the general population affected by problematic social media use.

This study aims to establish the prevalence of problematic use of social media in France. The investigators hypothesize that the prevalence will be close to 10%, which is the prevalence that has been found in other European countries in previous studies.

Eligibility

Sex
ALL
Min age
13 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 13 years or older. * Resident in France and French-speaking. * Does not object to participating in the study, and, for minors, whose parents also do not object to their participation. Exclusion Criteria: * Unable to understand and complete the questionnaire (e.g., non-French-speaking).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hospices Civils de Lyon Lyon France

More Hospices Civils de Lyon trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06798480 on ClinicalTrials.gov ↗ ← All trials in France